Compare Neurocrine Biosciences Inc (NBIX) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Packaging Corporation of America — how do they compare? Neurocrine Biosciences Inc trades at $140.75 (market cap $14.36B), while Packaging Corporation of America trades at $229.27 (market cap $20.49B). The key difference: Packaging Corporation of America is the larger of the two by market cap, and Packaging Corporation of America pays a 2.61% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Packaging Corporation of America for 45 Days on average.
| NBIX | PKG | |
|---|---|---|
Market Cap | $14.36B | $20.49B |
Volume | 1,237,180 | 493,499 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $257.43 |
52-Week Low | $123.10 | $191.68 |
Typical Hold Time | 23 Days | 45 Days |
Enterprise Value | $14.37B | $24.30B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Packaging Corporation of America (PKG) trades at $229.06, up 0.8% on the day, amid a bearish technical signal and mixed earnings performance. The stock shows strong profitability with a 7.26% net income margin and 14.79% ROE, though 2026 profit margins are projected to decline. Recent news highlights institutional buying and a steady dividend, while analyst consensus is a $272.43 price target with a 'Hold' bias.
PKG offers value through its dividend and stable business model but faces headwinds from cost pressures and negative cash flow trends. The stock's near-term performance hinges on Q3 2026 earnings results, with risks including margin compression and economic sensitivity. Upside exists if the company beats expectations and manages costs effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
